Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferi

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferi

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 35, Issue 46, 1 November 2017, Pages 6321-6328

Opokua Ofori-Anyinam, Geert Leroux-Roels, Mamadou Drame, Annelies Aerssens, Cathy Maes, Arshad Amanullah, Anne Schuind, Ping Li, Varsha K. Jain, Bruce L. Innis,